What is the latest news about lymphoma from ASH 2106? Lymphoma expert Dr. John Burke of Rocky Mountain Cancer Centers shares the three main elements of lymphoma news out of ASH: follicular lymphoma patients should expect obinatuzimab to become available sometime in 2017; mantle cell patients may see benefits from rituximab as a post-transplant maintenance therapy; and, unfortunately, trial outcomes for EPIC were negative with no overall advantage to diffuse large B-cell lymphomas patients.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo